Xenetic Biosciences, Inc., was founded in Nevada in August 2011. It is a clinical-stage biopharmaceutical company focused on the discovery, research and development of new generation biopharmaceuticals and novel orphan tumor treatments that may contribute to the improvement of human health worldwide. 

Xenetic Biosciences shares surge 23.23% after-hours after reporting 2025 financial results highlighting DNase technology advancements and preclinical data supporting cancer treatment potential.

XBIO News